Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386766 | 1.00 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL335753 | 1.00 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL12857733 | 0.95 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL5833103 | 0.94 | CXCR3 (0.89) | CXCR3CYP3A4 | |
| SCHEMBL27015148 | 0.94 | CXCR3 (0.89) | CXCR3CYP3A4 | |
| SCHEMBL27015149 | 0.93 | CXCR3 (0.87) | CXCR3CYP3A4 | |
| SCHEMBL14960668 | 0.91 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL12857869 | 0.89 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL13770583 | 0.89 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL15064525 | 0.88 | CXCR3 (1.00) | CXCR3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| WO-2022056115-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022056115-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2021188055-A1 | MODULATION OF CXCR3 CHEMOKINE SIGNALLING FOR OSTEOPOROSIS THERAPY | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2021-09-23 | — | — | WO | disclosed |
| US-10994082-B2 | Inhaler counter | ASTRAZENECA AB (SE) | 2021-05-04 | — | — | US | disclosed |
| US-20190175849-A1 | INHALER COUNTER | BANG & OLUFSEN MEDICOM A/S (DK) | 2019-06-13 | — | — | US | disclosed |
| US-20180339119-A1 | INHALER | BANG & OLUFSEN MEDICOM A/S (DK) | 2018-11-29 | — | — | US | disclosed |
| EP-2755707-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-11-14 | — | — | EP | disclosed |
| WO-2010042036-A1 | INHALER WITH AUDIBLE INDICATOR MEANS | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | WO | disclosed |
| US-20100051027-A1 | Entraining Powder In An Airflow | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| US-20100029732-A1 | Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| WO-2009154562-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| EP-2117542-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | AstraZeneca AB (SE) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009037503-A2 | NEW COMBINATION - 012 FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2009-03-26 | — | — | WO | disclosed |
| US-20080242649-A1 | New Combination 665 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008104776-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008096111-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096121-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | CXCR3 963/4885CYP3A4 1847/4885 |
| US-20080242649-A1 | New Combination 665 | NR3C2, PTGER2, GRK5 | CXCR3 248/4885CYP3A4 2963/4885 |
| US-20100029732-A1 | Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone | NR3C2, NR3C1, ARRB1 | CXCR3 406/4885CYP3A4 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.